Please login to the form below

Vytorin

This page shows the latest Vytorin news and features for those working in and with pharma, biotech and healthcare.

ezetimibe) and sister product Vytorin (ezetimibe plus simvastatin) - into a blockbuster franchise.

Merck & Co's anacetrapib data fails to generate much excitement

selling Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) in this therapeutic area despite a small effect on cardiovascular outcomes.
FDA panel rejects cardiovascular outcomes claim for Vytorin

Merck &Co fail to convince regulator's advisors. Merck &Co has failed to convince an FDA advisory committee that labelling for its cholesterol-lowering drug Vytorin should include a claim of ... The trial started around 10 years ago - shortly after
Merck hopes for another Keytruda with new immunotherapy deal

But Merck has been hit by the on-going erosion to its cardiovascular and cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin).
Relief as study finds no cardiovascular risk with Januvia

Overall pharma sales fell 2% on the back of declines for cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin) as well as immunotherapeutic Remicade (infliximab) which is facing biosimilar competition in
Merck's ezetimibe has 'modest' benefit when added to statins

under way nine years ago - shortly after Vytorin was first launched onto the market. ... Undeterred, Merck has said it will now file for approval of updated labelling for Vytorin and Zetia based on the results of IMPROVE-IT next year.

More from news
Approximately 4 fully matching, plus 27 partially matching documents found.

Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies

The pharma giant’s aim was to acquire the cholesterol inhibitor Vytorin, a product it had been hoping to develop before being been beaten to the finish line by its competitor.

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.